The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Open accessAbstract
Background The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the frameshift nature of indel mutations, which create novel open reading frames and a large quantity of mutagenic peptides highly distinct from self, might contribute to the immunogenic phenotype. Methods We analysed whole-exome sequencing data from 5777 solid tumours, spanning 19 cancer types from The Cancer Genome Atlas. We compared the proportion and number of indels across the cohort, with a subset of results replicated in two independent datasets. We assessed in-silico tumour-specific neoantigen predictions by mutation type with pan-cancer analysis, together with RNAseq profiling in renal clear cell carcinoma cases (n=392), to compare immune gene expression across patient subgroups. Associations between indel burden and treatment response were assessed across four checkpoint inhibitor datasets. Findings We observed renal cell carcinomas to have the highest proportion (0·12) and number of indel mutations across the pan-cancer cohort (p<2·2 × 10 −16 ), more than double the median proportion of indel mutations in all other cancer types examined. Analysis of tumour-specific neoantigens showed that enrichment of indel mutations for high-affinity binders was three times that of non-synonymous SNV mutations. Furthermore, neoantigens derived from indel mutations were nine times enriched for mutant specific binding, as compared with non-synonymous SNV derived neoantigens. Immune gene expression analysis in the renal clear cell carcinoma cohort showed that the presence of mutant-specific neoantigens was associated with upregulation of antigen presentation genes, which correlated ( r =0·78) with T-cell activation as measured by CD8-positive expression. Finally, analysis of checkpoint inhibitor response data revealed frameshift indel count to be significantly associated with checkpoint inhibitor response across three separate melanoma cohorts (p=4·7 × 10 −4 ). Interpretation Renal cell carcinomas have the highest pan-cancer proportion and number of indel mutations. Evidence suggests indels are a highly immunogenic mutational class, which can trigger an increased abundance of neoantigens and greater mutant-binding specificity. Funding Cancer Research UK, UK National Institute for Health Research (NIHR) at the Royal Marsden Hospital National Health Service Foundation Trust, Institute of Cancer Research and University College London Hospitals Biomedical Research Centres, the UK Medical Research Council, the Rosetrees Trust, Novo Nordisk Foundation, the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,905
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Self-citationGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Transcriptome and genome sequencing uncovers functional variation in humans
The Geuvadis Consortium, Lappalainen, T., Sammeth, M., Friedländer, M. R., ‘t Hoen, P. A. C., Monlong, J., Rivas, M. A., Gonzàlez-Porta, M., Kurbatova, N., Griebel, T., et al. (2013) · Nature · doi:10.1038/nature12531 · Cited by 1,888
Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,635
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Frameshift Mutations and the Genetic Code
Streisinger, G., Okada, Y., Emrich, J., Newton, J., Tsugita, A., Terzaghi, E., & Inouye, M. (1966) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1966.031.01.014 · Cited by 1,400
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
Allele-specific copy number analysis of tumors
Van Loo, P., Nordgard, S. H., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,226
Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., & Qin, J. (2000) · Genes & Development · doi:10.1101/gad.14.8.927 · Cited by 1,221
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,221
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
Self-citationRobbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
PyClone: statistical inference of clonal population structure in cancer
Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., & Shah, S. P. (2014) · Nature Methods · doi:10.1038/nmeth.2883 · Cited by 999
Şenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Van Allen, E. M., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1092-z · Cited by 968
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Davis, C. F., Ricketts, C. J., Wang, M., Yang, L., Cherniack, A. D., Shen, H., Buhay, C., Kang, H., Kim, S. C., Fahey, C. C., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.014 · Cited by 842
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Nielsen, M., Lundegaard, C., Blicher, T., Lamberth, K., Harndahl, M., Justesen, S., Røder, G., Peters, B., Sette, A., Lund, O., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000796 · Cited by 719
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Shukla, S. A., Rooney, M. S., Rajasagi, M., Tiao, G., Dixon, P. M., Lawrence, M. S., Stevens, J., Lane, W. J., Dellagatta, J. L., Steelman, S., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3344 · Cited by 675
D’Angelo, S. P., Larkin, J., Sosman, J. A., Lebbé, C., Brady, B., Neyns, B., Schmidt, H., Hassel, J. C., Hodi, F. S., Lorigan, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9258 · Cited by 650
Self-citationTumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 613
McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
The rules and impact of nonsense-mediated mRNA decay in human cancers
Lindeboom, R. G. H., Supek, F., & Lehner, B. (2016) · Nature Genetics · doi:10.1038/ng.3664 · Cited by 545
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.010 · Cited by 472
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Schwitalle, Y., Kloor, M., Eiermann, S., Linnebacher, M., Kienle, P., Knaebel, H. P., Tariverdian, M., Benner, A., & von Knebel Doeberitz, M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.015 · Cited by 387
Duan, F., Duitama, J., Al Seesi, S., Ayres, C. M., Corcelli, S. A., Pawashe, A. P., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141308 · Cited by 378
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
Nolan, E., Savas, P., Policheni, A. N., Darcy, P. K., Vaillant, F., Mintoff, C. P., Dushyanthen, S., Mansour, M., Pang, J.-M. B., Fox, S. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4922 · Cited by 295
Self-citationGenomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.009 · Cited by 259
Maby, P., Tougeron, D., Hamieh, M., Mlecnik, B., Kora, H., Bindea, G., Angell, H. K., Fredriksen, T., Elie, N., Fauquembergue, E., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3051 · Cited by 249
Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens
Linnebacher, M., Gebert, J., Rudy, W., Woerner, S., Yuan, Y. P., Bork, P., & von Knebel Doeberitz, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1298 · Cited by 234
Furney, S. J., Turajlic, S., Stamp, G., Nohadani, M., Carlisle, A., Thomas, J. M., Hayes, A., Strauss, D., Gore, M., van den Oord, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4204 · Cited by 229
Self-citationVariation in genomic landscape of clear cell renal cell carcinoma across Europe
Scelo, G., Riazalhosseini, Y., Greger, L., Letourneau, L., Gonzàlez-Porta, M., Wozniak, M. B., Bourgey, M., Harnden, P., Egevad, L., Jackson, S. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6135 · Cited by 193
HLA-Binding Properties of Tumor Neoepitopes in Humans
Fritsch, E. F., Rajasagi, M., Ott, P. A., Brusic, V., Hacohen, N., & Wu, C. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0227 · Cited by 190
Inhibition of Nonsense-Mediated RNA Decay by the Tumor Microenvironment Promotes Tumorigenesis
Wang, D., Zavadil, J., Martin, L., Parisi, F., Friedman, E., Levy, D., Harding, H., Ron, D., & Gardner, L. B. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05704-11 · Cited by 169
McDermott, D. F., Cheng, S., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., Dutcher, J. P., Logan, T. F., Curti, B. D., Ernstoff, M. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1520 · Cited by 160
The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis
Furney, S. J., Turajlic, S., Stamp, G., Thomas, J., Hayes, A. J., Strauß, D., Gavrielides, M., Xing, W., Gore, M. E., Larkin, J., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12279 · Cited by 147
Self-citationPrickett, T. D., Crystal, J. S., Cohen, C. J., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Yao, X., Wang, R., Gros, A., Li, Y. F., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0215 · Cited by 130
Williams, D. S., Bird, M., Jorissen, R. N., Yu, Y. L., Walker, F., Zhang, H. H., Nice, E. C., & Burgess, A. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0016012 · Cited by 128
Huang, J., El‐Gamil, M., Dudley, M. E., Li, Y. F., Rosenberg, S. A., & Robbins, P. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6057 · Cited by 127
Maby, P., Galon, J., & Latouche, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115943 · Cited by 62
Kuroda, K., Hibi, D., Ishii, Y., Takasu, S., Kijima, A., Matsushita, K., Masumura, K., Watanabe, M., Sugita‐Konishi, Y., Sakai, H., et al. (2013) · Mutagenesis · doi:10.1093/mutage/get054 · Cited by 49
Genetic Susceptibility to Renal Cell Carcinoma: The Role of DNA Double-Strand Break Repair Pathway
Margulis, V., Lin, J. M., Yang, H., Wang, W., Wood, C. G., & Wu, X. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0259 · Cited by 42
Fhit Deficiency-Induced Global Genome Instability Promotes Mutation and Clonal Expansion
Miuma, S., Saldivar, J. C., Karras, J. R., Waters, C. E., Paisie, C. A., Wang, Y., Jin, V. X., Sun, J., Druck, T., Zhang, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080730 · Cited by 29
Important role of indels in somatic mutations of human cancer genes
Yang, H., Zhong, Y., Peng, C. Y., Chen, J., & Tian, D. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-128 · Cited by 27
Lai, J., Zhou, Z. M., Tang, X., Gao, Z., Zhou, J., & Chen, S.-Q. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050739 · Cited by 24
Chow, S., Galvis, V., Pillai, M. R., Leach, R. J., Keene, E., Spencer-Shaw, A., Shablak, A., Shanks, J. H., Liptrot, T., Thistlethwaite, F. C., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0174-5 · Cited by 22
Bañobre, J. R., Anido, U., Abdulkader, I., López, J. R. A., López‐López, R., & García, J. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00250 · Cited by 19
OpEx - a validated, automated pipeline optimised for clinical exome sequence analysis
Ruark, E., Münz, M., Clarke, M., Renwick, A., Ramsay, E., Elliott, A., Seal, S., Lunter, G. A., & Rahman, N. (2016) · Scientific Reports · doi:10.1038/srep31029 · Cited by 10
Cited by
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Self-citationThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., El Dika, I. H., Segal, N., Shcherba, M., Sugarman, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201445 · Cited by 1,625
Metadata
- Authors
- Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., Chambers, T., Salgado, R., Savas, P., Loi, S., Birkbak, N. J., Sansregret, L., Gore, M., Larkin, J., Quezada, S. A., & Swanton, C.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 18
- Issue
- 8
- Pages
- 1009-1021
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2725858612
- Cited by
- 911
- References
- 70
- FWCI
- 37.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.